LPOXY Therapeutics: $28M Series A Sales Battle Card

🚀 Battle Card: LPOXY Therapeutics

• Dr. Larry Sutton, CEO 📧 larry@lpoxy.com

• This LPOXY Therapeutics sales trigger underscores investor confidence in non-antibiotic C. difficile prevention, accelerating partnerships for registrational trials. → Source

• High recurrence & hospital readmissions from C. difficile infections

• Rising antibiotic resistance limiting current treatment options

• Primary: Registrational trial support → Speed to FDA approval

• Expansion: Real-world evidence platform → Data-driven payer/provider buy-in

• HQ: Platte City, MO

• Employees: ≈ 25

• Rev: ≈ $0.5M

• Website: https://www.lpoxy.com/

🤼 Competitive Intel

• LabCorp/Covance — CRO / Clinical Trial Services
• Unique edge: Extensive global trial network
• Evaluated by CEO & Head of Clinical for scale

• Parexel — CRO / Clinical Trial Services
• Unique edge: Integrated regulatory consulting
• Evaluated by CMO & VP Regulatory Affairs

• ICON — CRO / eClinical Solutions
• Unique edge: Advanced data management platform
• Evaluated by VP Ops & Data Management

• IQVIA — CRO / Real-World Evidence
• Unique edge: Largest RWE database
• Evaluated by VP Medical Affairs for post-trial insights

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑Registrational trial support❑
PROOF_METRIC  = ❑≈ TBD❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Dr. Larry
COMPANY     = LPOXY Therapeutics
DEPT        = ≈ TBD
SIZE        = 25
BOTTLENECK  = High recurrence & hospital readmissions
EVENT       = Series A financing
DETAIL      = $28M Series A financing
PAIN        = High recurrence & hospital readmissions from C. difficile infections
SRC         = https://vcnewsdaily.com/lpoxy-therapeutics/venture-capital-funding/cvgwblcsqg
SIM_CO      = LabCorp
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = 50
EMP_EST     = ≈ 25
REV_EST     = ≈ $0.5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 25-person ≈ TBD

Dr. Larry—noticed your ≈ TBD team is ≈ 25.

That’s when High recurrence & hospital readmissions slows growth.

We helped LabCorp fix this with Registrational trial support.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ 50.

DM ≤45 words, TONE:
Saw your post about $28M Series A financing — High recurrence & hospital readmissions from C. difficile infections.  
Registrational trial support. ≈ TBD.  
Quick chat?